Sickle Cell Anemia Testing and Screening Market was valued at USD 494.8 million in 2025 and is expected to reach USD 1,579 million by 2035, growing at a CAGR of 12.30% from 2026–2035.
The worldwide market for Sickle Cell Anemia Testing and Screening is growing because of the increase in the prevalence rate of sickle cell disease, increase in government-driven programs for newborn and population screening, and advancements in diagnostic technology including molecular tests, point-of-care diagnostic tests, and AI-enabled blood smear analysis. Such technological advancements are contributing to improving the accuracy of early detection, lowering test costs, and increasing availability in resource-limited and high-burden settings. The sickle cell disease, which is the most common monogenic disease in the world, impacts about 300,000 infants per year, and the number is estimated to reach nearly 400,000 by 2050, especially in sub-Saharan Africa, India, Middle East, and global diasporas. Greater government investment, research by NIH, and FDA-approved gene therapies have added to the increased demand.